The nature and timing of specific copy number changes in the course of molecular progression in diffuse gliomas: Further elucidation of their genetic "life story"

Brain Pathology

Volumn 21, Issue 3, 2011, Pages 308-320

  Jeuken, Judith W M ^a,d   Sijben, Angelique ^a,b   Bleeker, Fonnet E ^c   Boots Sprenger, Sandra H E ^a   Rijntjes, Jos ^a   Gijtenbeek, Johanna M M ^d   Mueller, Wolf ^e   Wesseling, Pieter ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

EGFR amplification and rearrangements; loss of 1p and 19q; molecular pathology; PTEN and CDKN2A loss; TP53 and IDH1 mutations

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CANCER MODEL; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 19Q; CHROMOSOME 1P; COPY NUMBER VARIATION; CORRELATION ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE LOSS; GENE MUTATION; GENE REARRANGEMENT; GLIOBLASTOMA; HEMIZYGOSITY; HEMIZYGOSITY LOSS; HOMOZYGOSITY; HOMOZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PROGNOSIS; VALIDATION PROCESS;

BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; GLIOMA; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PATHOLOGY, MOLECULAR; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS;

EID: 79954568870     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2010.00447.x     Document Type: Article

References (50)

1. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A, (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602.
2. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, et al, (2000) Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 48: 825-830.
3. Bissola L, Eoli M, Pollo B, Merciai BM, Silvani A, Salsano E, et al, (2002) Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. Ann Neurol 52: 842-845. (Pubitemid 35403197)
4. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, et al, (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30: 7-11.
5. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein D, Hammond RR, et al, (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473-1479. (Pubitemid 28482012)
6. Cheng Y, Ng HK, Ding M, Zhang SF, Pang JC, Lo KW, (1999) Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors. J Neuropathol Exp Neurol 58: 120-128. (Pubitemid 29088936)
7. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK, (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79: 1381-1393. (Pubitemid 27143246)
8. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, et al, (2004) Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14: 121-130. (Pubitemid 38656383)
9. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S, et al, (2001) Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60: 248-262. (Pubitemid 32209644)
10. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al, (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118: 469-474.
11. Hashimoto N, Murakami M, Takahashi Y, Fujimoto M, Inazawa J, Mineura K, (2003) Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. Cancer 97: 2254-2261. (Pubitemid 36444069)
12. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von DA, (1997) Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7: 871-875. (Pubitemid 27346731)
13. Hegi ME, zur Hausen A, Ruedi D, Malin G, Kleihues P, (1997) Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. Int J Cancer 73: 57-63. (Pubitemid 27445991)
14. Hulsebos TJ, Troost D, Leenstra S, (2004) Molecular-genetic characterisation of gliomas that recur as same grade or higher grade tumours. J Neurol Neurosurg Psychiatry 75: 723-726. (Pubitemid 38526683)
15. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, Collins VP, (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11: 341-347.
16. Idbaih A, Marie Y, Pierron G, Brennetot C, Hoang-Xuan K, Kujas M, et al, (2005) Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 58: 483-487. (Pubitemid 41266639)
17. Idbaih A, Marie Y, Lucchesi C, Pierron G, Manie E, Raynal V, et al, (2008) BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 122: 1778-1786. (Pubitemid 351413424)
18. Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Jhung S, et al, (2000) Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 92: 983-990. (Pubitemid 30346517)
19. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al, (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7: 839-845. (Pubitemid 32708719)
20. Iuchi T, Namba H, Iwadate Y, Shishikura T, Kageyama H, Nakamura Y, et al, (2002) Identification of the small interstitial deletion at chromosome band 1p34-p35 and its association with poor outcome in oligodendroglial tumors. Genes Chromosomes Cancer 35: 170-175. (Pubitemid 34919974)
21. Jeuken JWM, Sprenger SHE, Wesseling P, Macville MVE, von Deimling A, Teepen HLJM, et al, (1999) Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol 58: 606-612. (Pubitemid 29264940)
22. Jeuken JWM, Sprenger SHE, Boerman RH, von Deimling A, Teepen HLJM, van Overbeeke JJ, Wesseling P, (2001) Subtyping of oligo-astrocytic tumours by comparative genomic hybridisation. J Pathol 194: 81-87.
23. Jeuken JWM, Sprenger SHE, Vermeer H, Kappelle AC, Boerman RH, Wesseling P, (2002) Chromosomal imbalances in primary oligodendroglial tumors and their recurrences; clues for malignant progression as detected by CGH. J Neurosurg 96: 559-564. (Pubitemid 34230212)
24. Jeuken JWM, Boots-Sprenger SHE, Wesseling P, (2004) Chromosomal imbalances in oligodendroglial tumors as detected by comparative genomic hybridization (CGH). In: Genomic and Molecular Neuro-Oncology., W Zhang, GN Fuller, (eds), pp. 185-198. Jones and Bartlett Publishers: Sudburry, Massachusetts.
25. Jeuken JWM, von Deimling A, Wesseling P, (2004) Molecular pathogenesis of oligodendroglial tumors. J Neurooncol 70: 161-181. (Pubitemid 39545730)
26. Jeuken JWM, van der Maazen RW, Wesseling P, (2006) Molecular diagnostics as a tool to personalize treatment in adult glioma patients. Technol Cancer Res Treat 5: 215-229. (Pubitemid 43946255)
27. Jeuken JWM, Cornelissen S, Boots-Sprenger SHE, Gijssen S, Wesseling P, (2006) Multiplex ligation-dependent probe amplification (MLPA): a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn 8: 433-443. (Pubitemid 44377925)
28. Jeuken JWM, Sijben A, Alenda C, Rijntjes J, Dekkers M, Boots-Sprenger SHE, et al, (2009) Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol 19: 661-671.
29. Kanner AA, Staugaitis SM, Castilla EA, Chernova O, Prayson RA, Vogelbaum MA, et al, (2006) The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg 104: 542-550.
30. Kleihues P, Cavenee WK, (2000) World Health Organization classification of tumours. Pathology and genetics. In: Tumours of the Nervous System., P Kleihues, WK Cavenee, (eds), pp. 9-70. International Agency for Research on Cancer (IARC) Press: Lyon, France.
31. Kraus JA, Wenghoefer M, Schmidt MC, von Deimling A, Berweiler U, Roggendorf W, et al, (2000) Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. J Neurol 247: 455-460. (Pubitemid 30433560)
32. Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, et al, (2007) Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66: 545-551. (Pubitemid 46869696)
33. Kujas M, Lejeune J, Benouaich-Amiel A, Criniere E, Laigle-Donadey F, Marie Y, et al, (2005) Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol 58: 322-326. (Pubitemid 41098891)
34. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, (2007) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer: Lyon, France.
35. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al, (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109. (Pubitemid 47103521)
36. Martinez R, Rohde V, Schackert G, (2010) Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol 96: 321-329.
37. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, et al, (2002) Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161: 313-319. (Pubitemid 34760797)
38. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H, (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15: 6002-6007.
39. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, et al, (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63: 1602-1607. (Pubitemid 36373650)
40. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G, (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120: 567-584.
41. Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, Louis DN, (2002) Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol 61: 58-63. (Pubitemid 34027720)
42. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, et al, (2002) Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61: 321-328. (Pubitemid 34266783)
43. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G, (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30: e57.
44. Smith JS, Perry A, Borell TJ, Lee HK, Fallon JO, Hosek SM, et al, (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18: 636-645. (Pubitemid 30078545)
45. Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, et al, (2002) Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8: 196-201. (Pubitemid 34101478)
46. van den Bent MJ, Looijenga LHJ, Langberg K, Dinjens W, Gravenland W, Uytdewilligen L, et al, (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97: 1276-1284. (Pubitemid 36237315)
47. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, et al, (1994) Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54: 649-652. (Pubitemid 24068319)
48. Vogazianou AP, Chan R, Backlund LM, Pearson DM, Liu L, Langford CF, et al, (2010) Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro Oncol 12: 664-678.
49. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H, (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174: 1149-1153.
50. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al, (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.